World's Best Scientists 2026 revealed!
Future Oncology
H-index 39

Future Oncology

1479-6694

Published by: Future Science Group

https://www.futuremedicine.com/journal/fon

Ranking & Metrics

Discipline name Position Best Scientists Publications D-Index
Medicine 418 463 469 38

Additional Metrics

Number of Best Scientists*: 564
Documents by Best Scientists*: 539
Top 100 Ranked Scientists*: 9
SCIMAGO H-index: 96
SCIMAGO SJR: 1.052
Impact Factor: 2.6

Overview

Top Research Topics at Future Oncology?

The journal investigates areas of study like Internal medicine, Oncology, Cancer, Cancer research and Chemotherapy. It primarily discusses Internal medicine topics, particularly Breast cancer, Clinical trial, Lung cancer, Disease and Prostate cancer. Non small cell is a major topic of Lung cancer research presented in Future Oncology.

Issues in Oncology were discussed, taking into consideration concepts from other disciplines like Colorectal cancer, Metastatic breast cancer, Radiation therapy and Immunotherapy. The study on Cancer presented in Future Oncology intersects with the topics under Bioinformatics. While work presented in Future Oncology provided substantial information on Cancer research, it also covered topics in Cancer cell, Metastasis and Immunology.

  • Internal medicine (49.90%)
  • Oncology (42.63%)
  • Cancer (21.40%)

What are the most cited papers published in the journal?

  • Role of systemic inflammatory response in predicting survival in patients with primary operable cancer (611 citations)
  • Fatty acid synthase as a potential therapeutic target in cancer (368 citations)
  • AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. (290 citations)

Research areas of the most cited articles at Future Oncology:

The most cited publications primarily focus on research topics in Internal medicine, Cancer, Oncology, Cancer research and Immunology. Internal medicine research in the published papers connects with the study of Endocrinology. The most cited papers facilitate discussions on Oncology that incorporate concepts from other fields like Breast cancer, Carcinoma, Targeted therapy and Immunotherapy.

What topics the last edition of the journal is best known for?

  • Cancer
  • Internal medicine
  • Gene

The previous edition focused in particular on these issues:

Future Oncology mostly deals with topics like Internal medicine, Oncology, Cancer, Chemotherapy and Clinical trial. Attendees of the journal participated in discussions that delve into both Internal medicine and In patient. The studies on Oncology discussed can also contribute to research in the domains of Retrospective cohort study, Hazard ratio, Stage (cooking), Colorectal cancer and Immunotherapy.

The studies tackled, which mainly focus on Cancer, apply to Cancer research as well. The study on Chemotherapy presented in Future Oncology intersects with subjects under the field of Disease. The concepts on Clinical trial presented in Future Oncology can also apply to other research fields, including Pembrolizumab and Placebo.

The most cited articles from the last journal are:

  • Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. (21 citations)
  • First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. (12 citations)
  • MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. (11 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

The top authors publishing in Future Oncology (based on the number of publications) are:

  • Marcello Migliore (35 papers) published 2 papers at the last edition, 1 less than at the previous edition,
  • Hampig Raphael Kourie (33 papers) published 4 papers at the last edition, 6 less than at the previous edition,
  • Dimitrios H Roukos (30 papers) published 1 paper at the last edition,
  • Liang Cheng (25 papers) published 2 papers at the last edition, 1 more than at the previous edition,
  • Joseph Kattan (25 papers) published 2 papers at the last edition, 3 less than at the previous edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Only papers with recognized affiliations are considered

The top affiliations publishing in Future Oncology (based on the number of publications) are:

  • University of Texas MD Anderson Cancer Center (120 papers) published 15 papers at the last edition, 4 more than at the previous edition,
  • Harvard University (79 papers) published 10 papers at the last edition, 5 less than at the previous edition,
  • Mayo Clinic (58 papers) published 6 papers at the last edition, 2 more than at the previous edition,
  • Memorial Sloan Kettering Cancer Center (58 papers) published 14 papers at the last edition, 9 more than at the previous edition,
  • Pfizer (55 papers) published 17 papers at the last edition, 6 more than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 9.29% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 19.51% were posted by at least one author from the top 10 institutions publishing in the journal. Another 9.76% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 16.59% of all publications and 54.15% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

  • Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
  • Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
  • Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
  • Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
  • Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Opportunities and Prospects in Oncology Research

The field of oncology research offers a myriad of exciting career opportunities for individuals interested in contributing to the advancement of cancer treatment. From laboratory scientists and clinical research coordinators to principal investigators and biostatisticians, a multitude of roles are available in this field. Laboratory scientists, for example, are often immersed in the forefront of cancer research, delving into the intricacies of cancer cell biology and genetics. On the other hand, research coordinators are a vital part of the research team, handling logistics and ensuring compliance with research protocols. Data in this field is often complex and needs expert handling to extract meaningful insights. This is where the role of a biostatistician comes in, making sense of the data gathered and guiding research decisions. Indeed, the field of oncology is wide and varied. Individuals interested in pursuing a career in this field are encouraged to seek a well-rounded education, encompassing both the theoretical knowledge and the practical skills necessary for success. Pursuing a degree or advanced studies can be a solid step towards forging a rewarding career in oncology research. Several well-respected institutions offer related courses and degree paths. For instance, you may want to check out the best nursing schools in Missouri, some of which offer specialized tracks in oncology nursing. According to data from research.com, these schools are well-regarded for the breadth and depth of their curriculum, as well as their commitment to employing experienced faculty. Over the years, the importance of oncology research has been amplified by the increasing prevalence of cancer. Consequently, the demand for skilled researchers is expected to remain strong. Whether you are a budding researcher or an experienced professional looking for an avenue to apply your skills, the field of oncology research offers the opportunity to contribute to a cause of significant global importance.

Top Publications

  • IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation

    Stephen P. Hack;Jessica Spahn;Minshan Chen;Ann Lii Cheng

    (2020)
    187 Citations
  • Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.

    Masahiro Tsuboi;Walter Weder;Carles Escriu;Collin Blakely

    (2021)
    132 Citations
  • FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements

    Tanios S Bekaii-Saab;Juan W Valle;Eric Van Cutsem;Lorenza Rimassa

    (2020)
    129 Citations
  • First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.

    Hyun Cheol Chung;Yung Jue Bang;Charles S Fuchs;Shu Kui Qin

    (2021)
    125 Citations
  • MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer.

    (2022)
    124 Citations
  • MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer.

    (2021)
    101 Citations
  • TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.

    Hope S Rugo;Aditya Bardia;Sara M Tolaney;Carlos Arteaga

    (2020)
    96 Citations
  • KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.

    Manish A. Shah;Jaafar Bennouna;Toshihiko Doi;Lin Shen

    (2021)
    89 Citations
  • The abscopal effect of radiation therapy.

    Daniel J Craig;Nisha S Nanavaty;Monika Devanaboyina;Laura Stanbery

    (2021)
    86 Citations
  • MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.

    Daniel V.T. Catenacci;Minori Rosales;Hyun Cheol Chung;Harry H. Yoon

    (2021)
    85 Citations

Related Online Degrees & Career Pathways

For those interested in the healthcare field but not pursuing an MD, online degrees in health information management offer a flexible and affordable alternative. Many students explore a health information management degree online to gain skills in organizing and managing medical data crucial for patient care and hospital operations.

Medical coding and billing is another popular pathway. Professionals in this field translate healthcare services into standardized codes used for insurance and billing purposes. Understanding the cpc certification is essential for advancing in this career, as it validates expertise and can increase salary potential.

Speaking of salary, it’s helpful to review information on how much do medical coders make to gauge whether this career aligns with your financial goals. The field has steady demand but varies by location and certification level.

Lastly, understanding the medical billing and coding job outlook helps prospective students evaluate long-term career stability. While the field offers entry points without extensive schooling, ongoing education and certification can lead to more opportunities and higher pay.

Best Scientists Contributing to This Journal

Recently Published Articles